Table I.
The prevalence of asthma in patients with COVID-19 in different countries or regions
| Country/region | Asthma prevalence in patients with COVID-19 |
Country/region | Asthma prevalence in patients with COVID-19 |
||||
|---|---|---|---|---|---|---|---|
| No. of studies | No. of patients | Calculated prevalence | No. of studies | No. of patients | Calculated prevalence | ||
| Egypt | 2 | 242 | 1.9% | United Kingdom | 1 | 17,535 | 14.5% |
| China mainland | 18 | 7,948 | 1.5% | Argentina | 1 | 78 | 1.3% |
| Taiwan | 1 | 100 | 3% | Brazil | 1 | 8,637 | 5.7% |
| Japan | 4 | 126 | 5.7% | Chile | 1 | 29 | 3.4% |
| South Korea | 1 | 9,148 | 16.9% | Cuba | 1 | 19 | 5.3% |
| Austria | 1 | 259 | 3.5% | Mexico | 1 | 211,003 | 2.8% |
| Belgium | 1 | 28 | 7.1% | Iran | 6 | 429 | 4.7% |
| Denmark | 1 | 175 | 11.4% | Iraq | 1 | 15 | 13.3% |
| Finland | 1 | 28 | 14.3% | Israel | 1 | 4,151 | 4.7% |
| France | 5 | 4,918 | 6.6% | Kuwait | 1 | 1,096 | 3.9% |
| Germany | 3 | 88 | 10.7% | Saudi Arabia | 1 | 1,519 | 3.6% |
| Greece | 1 | 90 | 3.3% | United Arab Emirates | 1 | 34 | 8.8% |
| Ireland | 2 | 239 | 10.9% | Turkey | 2 | 1,017 | 6.2% |
| Italy | 2 | 6,314 | 1.1% | Canada | 1 | 117 | 12.0% |
| Norway | 1 | 66 | 10.6% | United States | 48 | 97,195 | 10.2% |
| Poland | 1 | 28 | 7.1% | Bangladesh | 1 | 103 | 5.8% |
| Portugal | 1 | 20,293 | 1.4% | India | 1 | 280 | 4.3% |
| Spain | 7 | 8,204 | 4.9% | Pakistan | 1 | 30 | 5.3% |
| Sweden | 1 | 27 | 11.1% | Philippines | 1 | 8,212 | 3.2% |
| Switzerland | 3 | 328 | 6.5% | ||||
For each country/region with 2 or more studies reporting the prevalence of asthma in patients with COVID-19, a meta-analysis was performed to estimate the pooled prevalence. For countries or regions with only 1 available study reporting asthma prevalence in patients with COVID-19, asthma prevalence was calculated as (total patients with COVID-19 with asthma)/(total patients with COVID-19).